Release Date: March 05, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: How does the 9.6% growth in P&C renewals reconcile with the 4-6% guidance? A: Francois de Varenne, Deputy CEO and CFO, explained that the 9.6% growth reflects the success of the January 1 renewals, but the company maintains its 4-6% guidance due to factors like the lag effect in translating gross premium to insurance revenue and the impact of large commutations. Jean-Paul Conoscente, CEO of SCOR P&C, added that the growth in the Alternative Solutions portfolio affects the ISR and IFRS 17 figures.
Q: Can you clarify the impact of one-offs on net income and future buffer building? A: Francois de Varenne stated that the Q4 results include minimal one-offs, with a strong underlying performance in P&C and Life & Health. The effective tax rate was lower due to strategic profit repatriation. The company has already exceeded its buffer-building target significantly and will only pursue further buffer building opportunistically.
Q: What is the status of the P&C reserving buffer and future plans? A: Francois de Varenne confirmed that SCOR has surpassed its EUR300 million buffer target well ahead of schedule. The company will now adopt an opportunistic approach to buffer building, depending on profitability, but has no specific targets beyond the current achievement.
Q: What are the expectations for Life & Health experience variances in 2025? A: Francois de Varenne noted that while there was a negative experience variance in the US in Q4, the company is comfortable with its updated assumptions. The guidance for the insurance service result in 2025 accounts for some volatility, but significant improvements are expected as management actions continue.
Q: What are the key risks to maintaining stable technical margins in 1/1 renewals? A: Jean-Paul Conoscente highlighted that the main risk is how prices hold for upcoming renewals. The California wildfires and early consumption of cat budgets may stabilize prices, but the company remains cautious about managing its cat budget.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。